FAQs
What is the Operations Rotational Development Program (ORDP)?
The Operations Rotational Development Program (ORDP) is a rotational leadership development program that prepares recent graduates for successful contributions to Roche/Genentech's Pharma Technical Operations (PT).
What locations are involved in the ORDP?
The primary location for the ORDP is in Mississauga, Canada, with opportunities to support work at facilities in Hillsboro, Oregon; South San Francisco; and Oceanside California.
What qualifications are required to apply for the ORDP?
Applicants must have a Bachelor's or Master's degree in disciplines such as Biochemical, Biomedical, Chemical, Industrial, or Mechanical Engineering, Biochemistry, Biology, Chemistry, Operations, Computer Science, Data and Analytics, or related fields, along with operations-related internships or work experience.
How long do the rotational assignments last?
Each rotational assignment lasts for six months.
Are there opportunities for further career development in the ORDP?
Yes, during the fourth rotational assignment, analysts have the opportunity to apply for open positions at Genentech to further their career goals.
What types of projects will ORDP analysts work on?
ORDP analysts will work on both individual and team projects that support specific business needs throughout Pharma Technical Operations (PT).
Is this position eligible for relocation support?
No, this position is not eligible for relocation support.
What is the expected salary range for this position?
The expected salary range for this position is CAD $70,150 - $130,325, with actual pay determined based on experience, qualifications, geographic location, and other job-related factors.
What benefits are available to ORDP analysts?
ORDP analysts are eligible for Roche’s standard vacation and benefits package, which includes various employee benefits detailed in the company's materials.
Are there any COVID-19 vaccination requirements for this position?
Yes, Roche requires all new employees who work in Canada to be fully vaccinated against COVID-19 on their start date, with exceptions available for specific medical reasons or other valid reasons protected by applicable human rights laws.